Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Covalon Technologies Ltd V.COV

Alternate Symbol(s):  CVALF

Covalon Technologies Ltd. is a patient-driven medical device company. Through a portfolio of patented technologies and solutions for advanced wound care, infection prevention, and medical device coatings, the Company offers gentler and more compassionate options for patients to heal with less infections, less pain, and better outcomes. Its solutions are designed for patients and made for care providers. It leverages its patented medical technology platforms and expertise in two ways: by developing products that are sold under Covalon’s name and by developing and commercializing medical products for other medical companies under development and license contracts. It provides a range of specialized medical devices, medical dressings and advanced medical technology designed for infection prevention, complex wound closure and perioperative care. Its perioperative care solutions provide antimicrobial protection of pre-operative skin, through postoperative incision care to scar prophylaxis.


TSXV:COV - Post by User

Bullboard Posts
Post by TheRock07on Aug 28, 2016 7:27am
174 Views
Post# 25184336

Iran+ deals will be a bigger market than Saudi Arabia

Iran+ deals will be a bigger market than Saudi Arabia

Iran has more than twice the population as KSA and a much more extensive healthcare system that is now growing rapidly with the lifting of embargoes .


Colvalon has been building a base in Iran for several years And recently entered into a distribution agreement to make ALL of its entire product line available for distribution to the Ministry of Health and also the private hospital systems in Iran.

This is a substantial success for Covalon.
Their products now have the opportunity to be category leaders for the Iranium infection and wound care space.


Covalon also has a break through in Qatar where it's flagship advanced wound care product ColActive Plus Ag has been trialled successfully over the past several months in the eight-hospital system managed by Hamad Medical Corp., the main provider of secondary and tertiary health care in Qatar and one of the leading hospital providers in the Middle East.

Covalen expects to immediately introduce its IV Clear, SurgiClear and CovaWound product lines to Hamad Medical's five specialist hospitals and three community hospitals in Qatar.

 Covalon has also commenced the process of registering its full product line with SEHA Abu Dhabi Health Services Company, which owns and operates 12 hospitals, 62 ambulatory and primary health care centres, and two blood banks, across the entire United Arab Emirates.

Combined, these three deals have a market potential several times larger than KSA and Covalon's entire product line is being made available in two of these.

Over the next year or so, these three distribution deals will progressively escalate 
Covalon's sales..

Bullboard Posts